Last reviewed · How we verify
phytoestrogen
At a glance
| Generic name | phytoestrogen |
|---|---|
| Also known as | Klimadynon |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Estrogen, Diet, Genetics and Endometrial Cancer
- PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition (PHASE2)
- Examining the Impact of Phytoestrogens Supplementation on the Gene Expression, and Premenstrual Syndrome in Primenopausal Women (NA)
- Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression (NA)
- Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women (PHASE2, PHASE3)
- Soy Isoflavones and Breast Cancer Risk Reduction (PHASE2)
- Nutritional Intervention and DNA Damage of Patients With HBOC (NA)
- PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- phytoestrogen CI brief — competitive landscape report
- phytoestrogen updates RSS · CI watch RSS
- Cairo University portfolio CI